Buy Eris Lifesciences; target of Rs 870: Motilal Oswal
Motilal Oswal is bullish on Eris Lifesciences recommended buy rating on the stock with a target price of Rs 870 in its research report dated May 05, 2022.07-05-2022
07-05-2022
Eris Lifesciences Ltd - 540596 - AUDIO RECORDING OF THE EARNINGS CONFERENCE CALL
Dear Sir/Madam, In accordance with the applicable requirements and regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable Regulations, we wish to inform you that the Audio Recording of the Earnings Conference Call in connection with the Consolidated and Standalone Audited Financial Results of the Company for the Financial Year ended March 31, 2022, held on May 4, 2022, is available on the website of the Company and can be accessed through the following link: Link: https://eris.co.in/financials/ (File name: Q4 FY22 Earnings Call Recording)05-05-2022
Earnings Call for Q4FY22 of Eris Lifesciences
Conference Call with Eris Lifesciences Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.04-05-2022
Eris Lifesciences steps in dermatology therapy biz, to buy Oaknet Healthcare for 650 cr
For the acquisition, Eris will finance 300 crore through internal accruals and 350 crore through borrowings. The acquisition will be carried through a share purchase agreement. Post the completion, Oaknet will become a wholly-owned subsidiary of Eris.04-05-2022
Eris Lifesciences Ltd - 540596 - INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)
In accordance requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para B(5) of Part A of Schedule III and SEBI Circular CIR/CFD/CMD/4/2015 September 09, 2015, details attached herein may be taken on record. Reason for delay: The Company has been a debt free company for a major part of its existence. A disclosure of loan, of the magnitude covered herein, could have therefore fuelled speculations about an impending acquisition. As that situation would have been premature, undesirable and prejudicial to the interests of the investors, the company made a choice of making the disclosure appearing herein after the acquisition announcement w.r.t. Oaknet Healthcare P.Ltd. achieved finality.04-05-2022
Eris Lifesciences Ltd - 540596 - INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015
In accordance requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A (1) of Part A of Schedule III and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, details attached herein may be taken on record The details of the same will be uploaded on the website of the Company.04-05-2022
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Acquisition
In accordance requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A (1) of Part A of Schedule III and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, details attached herein may be taken on record The details of the same will be uploaded on the website of the Company.04-05-2022
Eris Lifesciences Ltd - 540596 - OUTCOME OF THE BOARD MEETING
In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their meeting held on 3rd May, 2022 has inter alia, transacted the following business: ? Appointment of M/s Ravi Kapoor & Associates, Practicing Company Secretaries, Ahmedabad as the Secretarial Auditor of the Company for the financial year 2022-23. The Brief profile of M/s. Ravi Kapoor & Associates is enclosed herewith. ? Appointment of M/s Kiran J. Mehta & Co., Cost Accountants, as the Cost Auditors of the Company for the financial year 2022-23. The Brief profile of M/s Kiran J Mehta & Co. is enclosed herewith.03-05-2022
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached investor presentation made by the Company.03-05-2022